At the time of writing, Travere Therapeutics Inc [TVTX] stock is trading at $25.16, down -3.49%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TVTX shares have gain 2.11% over the last week, with a monthly amount glided 0.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup reaffirmed its Buy rating on June 11, 2025, and dropped its price target to $32. On January 10, 2025, Cantor Fitzgerald initiated with a Overweight rating. Wells Fargo upgraded its rating to a Overweight and increased its price target to $27 on October 21, 2024. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim upgraded its rating to Buy for this stock on September 09, 2024, but kept the price target unchanged to $25. In a note dated March 27, 2024, Guggenheim downgraded a Neutral rating on this stock.
For the past year, the stock price of Travere Therapeutics Inc fluctuated between $12.91 and $28.69. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $25.16 at the most recent close of the market. An investor can expect a potential return of 39.11% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
According to Travere Therapeutics Inc [NASDAQ:TVTX], the company’s sales were 333.87M for trailing twelve months, which represents an 111.49% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.51%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -7.18 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of12.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Travere Therapeutics Inc [NASDAQ:TVTX] has a current ratio of 2.00. In addition, the Quick Ratio stands at 1.98 and the Cash Ratio stands at 0.4. Considering the valuation of this stock, the price to sales ratio is 6.72, the price to book ratio is 68.46.
Transactions by insiders
Recent insider trading involved REED ELIZABETH E, Chief Legal Officer and GC, that happened on Sep 22 ’25 when 10000.0 shares were sold. Officer, ELIZABETH REED completed a deal on Sep 22 ’25 to buy 10000.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Cline Christopher R. sold 454.0 shares on Sep 03 ’25.
